AUTOLUS THERAPEUTICS PLC |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.955 USD | +0.64% |
|
-3.89% | -38.66% |
Presenter SpeechRobert Dolski (Executives)Good morning, everyone here in San Diego and to thos...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Autolus Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. It is focused on chimeric antigen receptor (CAR)-T cell therapy. Using a suite of proprietary and modular T cell programming technologies, it is engineering targeted, controlled and highly active T cell therapy product candidates that are designed to recognize target cells, break down their defense mechanisms and eliminate these cells. It has a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. Its products pipeline includes obe-cel (FELIX), obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting T Cell Receptor Beta Constant (TRBC) 1 and TRBC 2.
Calendar
17/05/2024
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
3.93
USD
Average target price
10.54
USD
Spread / Average Target
+168.31%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -38.66% | 1.05B | |
| +7.45% | 111B | |
| +11.22% | 106B | |
| -12.49% | 22.24B | |
| +0.44% | 21.25B | |
| -4.18% | 18.97B | |
| -37.85% | 18.52B | |
| -8.70% | 16.81B | |
| +37.63% | 12.54B | |
| -24.41% | 8.09B |
- Stock Market
- Equities
- AUTL Stock
- News Autolus Therapeutics plc
- Transcript : Autolus Therapeutics plc - Shareholder/Analyst Call
